Bacterial genome engineering using CRISPR RNA-guided transposases.
| Autor: | Gelsinger DR; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA., Vo PLH; Department of Molecular Pharmacology and Therapeutics, Columbia University, New York, NY, USA., Klompe SE; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA., Ronda C; Department of Systems Biology, Columbia University, New York, NY, USA., Wang H; Department of Systems Biology, Columbia University, New York, NY, USA., Sternberg SH; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BioRxiv : the preprint server for biology [bioRxiv] 2023 Mar 21. Date of Electronic Publication: 2023 Mar 21. |
| DOI: | 10.1101/2023.03.18.533263 |
| Abstrakt: | CRISPR-associated transposons (CASTs) have the potential to transform the technology landscape for kilobase-scale genome engineering, by virtue of their ability to integrate large genetic payloads with high accuracy, easy programmability, and no requirement for homologous recombination machinery. These transposons encode efficient, CRISPR RNA-guided transposases that execute genomic insertions in E. coli at efficiencies approaching ~100%, generate multiplexed edits when programmed with multiple guides, and function robustly in diverse Gram-negative bacterial species. Here we present a detailed protocol for engineering bacterial genomes using CAST systems, including guidelines on the available homologs and vectors, customization of guide RNAs and DNA payloads, selection of common delivery methods, and genotypic analysis of integration events. We further describe a computational crRNA design algorithm to avoid potential off-targets and CRISPR array cloning pipeline for DNA insertion multiplexing. Starting from available plasmid constructs, the isolation of clonal strains containing a novel genomic integration event-of-interest can be achieved in 1 week using standard molecular biology techniques. Competing Interests: Conflict of interest Columbia University has filed a patent application related to this work for which P.L.V.., S.E.K., and S.H.S. are inventors. S.H.S. is a co-founder and scientific advisor to Dahlia Biosciences, a scientific advisor to CrisprBits and Prime Medicine, and an equity holder in Dahlia Biosciences and CrisprBits. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|